» Articles » PMID: 26055242

Single-pulse Transcranial Magnetic Stimulation (sTMS) for the Acute Treatment of Migraine: Evaluation of Outcome Data for the UK Post Market Pilot Program

Overview
Journal J Headache Pain
Publisher Biomed Central
Date 2015 Jun 10
PMID 26055242
Citations 45
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Single pulse transcranial magnetic stimulation (sTMS) is a novel treatment for acute migraine. Previous randomised controlled data demonstrated that sTMS is effective and well tolerated in the treatment of migraine with aura. The aim of the programme reported here was to evaluate patient responses in the setting of routine clinical practice.

Methods: Migraine patients with and without aura treating with sTMS had an initial review (n = 426) and training call, and then participated in telephone surveys at week six (n = 331) and week 12 during a 3-month treatment period (n = 190).

Results: Of patients surveyed with 3 month data (n = 190; episodic, n = 59; chronic, n = 131), 62 % reported pain relief, finding the device effective at reducing or alleviating migraine pain; in addition there was relief reported of associated features: nausea- 52 %; photophobia- 55 %; and phonophobia- 53 %. At 3 months there was a reduction in monthly headache days for episodic migraine, from 12 (median, 8-13 IQ range) to 9 (4-12) and for chronic migraine, a reduction from 24 (median, 16-30 IQ range) to 16 (10-30). There were no serious or unanticipated adverse events.

Conclusion: sTMS may be a valuable addition to options for the treatment of both episodic and chronic migraine.

Citing Articles

Hyperacusis questionnaire and event-related potential correlation in migraine patients.

Qi L, Jilei Z, Lisheng Y, Yuanyuan J Sci Rep. 2024; 14(1):14117.

PMID: 38898084 PMC: 11187201. DOI: 10.1038/s41598-024-65014-3.


The complex landscape of TMS devices: A brief overview.

Gutierrez-Muto A, Bestmann S, Sanchez de la Torre R, Pons J, Oliviero A, Tornero J PLoS One. 2023; 18(11):e0292733.

PMID: 38015924 PMC: 10684101. DOI: 10.1371/journal.pone.0292733.


Efficacy of recurrent transcutaneous magnetic stimulation in the treatment of diabetic peripheral neuropathy: Multicenter randomized trial.

Rao V, Kim Y, Ghazi A, Park J, Munir K Pain Pract. 2023; 23(8):914-921.

PMID: 37395169 PMC: 10761591. DOI: 10.1111/papr.13269.


Excitation-Inhibition Imbalance in Migraine: From Neurotransmitters to Brain Oscillations.

OHare L, Tarasi L, Asher J, Hibbard P, Romei V Int J Mol Sci. 2023; 24(12).

PMID: 37373244 PMC: 10299141. DOI: 10.3390/ijms241210093.


Migraine: from pathophysiology to treatment.

Puledda F, Martins Silva E, Suwanlaong K, Goadsby P J Neurol. 2023; 270(7):3654-3666.

PMID: 37029836 PMC: 10267278. DOI: 10.1007/s00415-023-11706-1.


References
1.
Goadsby P . Therapeutic prospects for migraine: can paradise be regained?. Ann Neurol. 2015; 74(3):423-34. DOI: 10.1002/ana.23996. View

2.
Goadsby P, Sprenger T . Current practice and future directions in the prevention and acute management of migraine. Lancet Neurol. 2010; 9(3):285-98. DOI: 10.1016/S1474-4422(10)70005-3. View

3.
Coeytaux R, Kaufman J, Chao R, Mann J, DeVellis R . Four methods of estimating the minimal important difference score were compared to establish a clinically significant change in Headache Impact Test. J Clin Epidemiol. 2006; 59(4):374-80. DOI: 10.1016/j.jclinepi.2005.05.010. View

4.
Dodick D, Schembri C, Helmuth M, Aurora S . Transcranial magnetic stimulation for migraine: a safety review. Headache. 2010; 50(7):1153-63. DOI: 10.1111/j.1526-4610.2010.01697.x. View

5.
Lipton R, Dodick D, Silberstein S, Saper J, Aurora S, Pearlman S . Single-pulse transcranial magnetic stimulation for acute treatment of migraine with aura: a randomised, double-blind, parallel-group, sham-controlled trial. Lancet Neurol. 2010; 9(4):373-80. DOI: 10.1016/S1474-4422(10)70054-5. View